Vaccine for early breast cancer (DCIS)
Part of Cancer clinical trials.
This trial tests a vaccine that targets a protein (MUC1) found in early breast cancer cells. It's for women with ER+ DCIS who are planning surgery, to see if the vaccine can help prevent the cancer from coming back or getting worse.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 or older.
- You have been diagnosed with a very early breast cancer called DCIS (ductal carcinoma in situ) that is estrogen receptor positive (ER+).
- You are planning to have surgery to remove the DCIS.
- You have not had invasive breast cancer (cancer that has spread beyond the milk ducts).
- You do not have an autoimmune disease that requires immune-suppressing medication.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called CAN1012 in people with pre-cancerous breast conditions called DCIS or LCIS. It aims to see if the drug can help before invasive cancer develops.
This trial tests a new way to mark the area where breast cancer is removed during lumpectomy with oncoplastic reconstruction. The goal is to make follow-up radiation more precise and reduce the need for additional surgeries.
This trial tests whether active surveillance (close monitoring) is a good option for certain patients with hormone-positive DCIS who have positive surgical margins after initial surgery. You would receive no immediate additional treatment—just regular imaging and check-ups.
This trial tests a vaccine made from a lung-cancer target (MUC1) to help your immune system recognize and fight the cancer. It is designed to measure immune response and safety, and it may help some people develop a stronger anti-cancer immune reaction.
This Phase 1 study tests a vaccine (H2NVAC) given before surgery to help the body fight HER2-expressing ductal carcinoma in situ (DCIS) that has not been removed yet. Because it’s early-stage, the main goal is to check safety and learn how the treatment may work.
This Phase 1 trial tests a new study drug called DC1 given before standard breast cancer treatments. It focuses on people with HER2-negative breast cancer that is “hormone negative” or “hormone low,” aiming to see if the treatment is safe and whether it may work before surgery or other local therapy.
Hear when a new Ductal Carcinoma in Situ trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.